NL2025294B1 - Antimicrobial peptide for treatment and controlling virus infections - Google Patents
Antimicrobial peptide for treatment and controlling virus infections Download PDFInfo
- Publication number
- NL2025294B1 NL2025294B1 NL2025294A NL2025294A NL2025294B1 NL 2025294 B1 NL2025294 B1 NL 2025294B1 NL 2025294 A NL2025294 A NL 2025294A NL 2025294 A NL2025294 A NL 2025294A NL 2025294 B1 NL2025294 B1 NL 2025294B1
- Authority
- NL
- Netherlands
- Prior art keywords
- seq
- antimicrobial peptide
- peptide
- virus
- amino acid
- Prior art date
Links
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims abstract description 54
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims abstract description 54
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 53
- 230000009385 viral infection Effects 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 21
- 241000282414 Homo sapiens Species 0.000 claims abstract description 18
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 208000036142 Viral infection Diseases 0.000 claims abstract description 8
- 239000003085 diluting agent Substances 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 241000700605 Viruses Species 0.000 abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 150000001413 amino acids Chemical group 0.000 description 39
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000007363 ring formation reaction Methods 0.000 description 10
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108010068380 arginylarginine Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 241000233866 Fungi Species 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 5
- -1 aromatic amino acid Chemical class 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 102000050459 human LTF Human genes 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- ZRGNRZLDMUACOW-HERUPUMHSA-N Ala-Cys-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N ZRGNRZLDMUACOW-HERUPUMHSA-N 0.000 description 4
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 4
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 4
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010058874 Viraemia Diseases 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 108010004073 cysteinylcysteine Proteins 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- JISIQDCOHJOOPU-WFBYXXMGSA-N Trp-Cys-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O JISIQDCOHJOOPU-WFBYXXMGSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 2
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- HQZGVYJBRSISDT-BQBZGAKWSA-N Cys-Gly-Arg Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O HQZGVYJBRSISDT-BQBZGAKWSA-N 0.000 description 2
- 206010012504 Dermatophytosis Diseases 0.000 description 2
- YADSXULAFMJZRL-QEJZJMRPSA-N Gln-Trp-Cys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)N)N YADSXULAFMJZRL-QEJZJMRPSA-N 0.000 description 2
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- 241001460074 Microsporum distortum Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- OXVPMZVGCAPFIG-BQFCYCMXSA-N Val-Gln-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N OXVPMZVGCAPFIG-BQFCYCMXSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- UKVGHFORADMBEN-GUBZILKMSA-N Cys-Arg-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UKVGHFORADMBEN-GUBZILKMSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to an antimicrobial peptide for use in a method of preventing or treating and/or controlling viral infections. The invention further relates to a composition comprising an antimicrobial peptide and a pharmaceutically acceptable diluent or excipient, for use in a method of preventing or treating and/or controlling virus and/or virus—infection related disorders. The invention also relates to a method of treating a patient suffering from virus—infection related disorders, the method comprising administering a therapeutically effective amount of an antimicrobial peptide thereof the human or animal is affected by viruses and or disorders.
Description
TECHNICAL FIELD OF THE INVENTION The invention relates to the treatment and to the controlling of virus infections with an antimicrobial peptide. The invention further relates to an antimicrobial peptide for use in the treatment or for use in the controlling of virus infections and to a pharmaceutical composition comprising such antimicrobial peptide.
BACKGROUND OF THE INVENTION With the recent emergence of a pandemic of Corona virus (Covid-19), the need for improved vaccines against viral infections has become an international priority. Although strategies for vaccine development have improved significantly over time, we are still facing major challenges in delivering those vaccines by 2020.
New technologies of the next generation, as represented by real-time DNA sequencing, provide a lot of data on viral pathogens and host cells. This allows us to 'mine' the genomic sequence for putative vaccine candidates or targets, allowing for a rational approach to vaccine design. The problem here is that it takes a lot of time and research to achieve this. It is expected that the first vaccine against Covid-19 will not come on the market until the end of 2020. Unfortunately, we cannot prevent that for a lot of people this too late become available.
SUMMARY OF THE INVENTION The current invention provides an improved therapy option and improved controlling option for dermatophytosis in that, in one aspect, it provides an antimicrobial peptide for use in a method of preventing or treating or controlling virus infections, wherein the antimicrobial peptide for use in a method of preventing or treating and/or controlling a virus infection in a human or animal subject, wherein the antimicrobial peptide comprises or consists of any one of the amino acid sequences RRRRSVQWCA [SEQ ID NO: 1], GRRRRSVQWCA [SEQ ID NO: 3}, ACWQVSRRRR [SEQ ID NO: 2}, ACWQVSRRRRG [SEQ ID NO: 4], CGRRRRSVQWCA [SEQ ID NO: 5}, or a functional mutant thereof. Such antimicrobial peptide has been shown to be very effective in combating virus infections.
The antimicrobial peptide further shows no toxicity or other side-effects when topically applied orally or topical in human subjects suffering from infection of viruses.
In addition to innate immunity, in which antimicrobial proteins and peptides are of great value, plays acquired immunity (the evocation of specific antiviral antibodies) a role against the protection of viruses. Under immune compromised conditions, such as diseases, diabetes, the sensitivity to these viral infections increases greatly. Strengthening our own defense system (first line of defense) could be another approach in the fight against this virus. These cells (called Host defense peptides - HDPs) are multifunctional inducers and effectors of our immunity. immunomodulatory activity also directly respond to viral infectious processes. Whose antiviral activity, demonstrated against both envelope containing and naked viruses, is in the early phase of infection, preventing the virus from entering the host cell. Binding to specific receptors, viral parts or both. A number of peptides can bind to these binding sites, greatly inhibiting the attachment of a virus to its “target” cell, the first stage of the virus infection. On the other hand, the peptide can bind directly to the envelope protein, thus inhibiting the infectivity of the virus.
It has been demonstrated in experimental research that these peptides are active against various viruses, including HCV, Hepatitis B, HIV, and HPV. The advantage of these peptides is that they are endogenous to the body, so they do not cause rejection or adverse effects to the host. Safety profile has been clinically tested in HSCT patients. Experimental research has shown that strong inhibition of viruses can be achieved with relatively low doses. It is also commercially attractive, due to the favorable production price.
In a second aspect, the invention provides a composition comprising an antimicrobial peptide and a pharmaceutically acceptable diluent or excipient, for use in a method of preventing or treating and/or controlling a virus infection in a human or animal subject, wherein the antimicrobial peptide comprises or consists of any one of the amino acid sequences RRRRSVQWCA [SEQ ID NO: 1}, GRRRRSVQWCA [SEQ ID NO: 3], ACWQVSRRRR [SEQ ID NO: 2}, ACWQVSRRRRG {SEQ ID NO: 4],
CGRRRRSVQWCA {SEQ ID NO: 5}, or a functional mutant thereof. Such composition is preferably odourless and colourless in order to improve patients’ compliance. In a third aspect, the invention provides a method of treating a patient suffering from virus infections, the method comprising administering a therapeutically effective amount of an antimicrobial peptide comprises or consists of any one of the amino acid sequences RRRRSVQWCA [SEQ ID NO: 1}, GRRRRSVQWCA [SEQ ID NO: 3}, ACWQVSRRRR [SEQ ID NO: 2}, ACWQVSRRRRG [SEQ ID NO: 4}, CGRRRRSVOWCA [SEQ ID NO: 5}, or a functional mutant thereof. AMINO ACID SEQUENCES & SEQ ID NOs Amino acid sequence relating to human lactoferrin peptide 2-11 (hLF2- 11): Arg Arg Arg Arg Ser Val Gln Trp Cys Ala {SEQ ID NO: 1] Amino acid sequence relating to artificial reverse human lactoferrin peptide 2-11 (Reverse hLF2-11): Ala Cys Trp Gln Val Ser Arg Arg Arg Arg [SEQ ID NO: 2] Amino acid sequence relating to human lactoferrin peptide 1-11 (hLFI- 11): Gly Arg Arg Arg Arg Ser Val Gln Trp Cys Ala {SEQ ID NO: 3} Amino acid sequence relating to artificial reverse human lactoferrin peptide 1-11 (Reverse hLF1-11): Ala Cys Trp Gln Val Ser Arg Arg Arg Arg Gly [SEQ ID NO: 4] Artificial Amino acid sequence relating to human lactoferrin peptide 1-11 provided with an N-terminal Cysteine (cysteine - hLFI-11): Cys Gly Arg Arg Arg Arg Ser Val Gln Trp Cys Ala [SEQ ID NO: 5]
DEFINITIONS The embodiments of the invention described herein can operate in combination and cooperation, unless specified otherwise. Furthermore, the various embodiments, although referred to as “preferred” or “e.g.” or “for example” or “in particular” are to be construed as exemplary manners in which the invention may be implemented rather than as limiting the scope of the invention. The term “comprising”, used in the claims, should not be interpreted as being restricted to the elements, compounds or steps listed thereafter; it does not exclude other elements or compounds or steps. It needs to be interpreted as specifying the presence of the stated features. integers, steps, compounds or components as referred to, but does not preclude the presence or addition of one or more other features, integers, steps, compounds or components, or groups thereof. Thus, the scope of the expression “a composition comprising A and B” should not be limited to a composition consisting only of compounds A and B, rather with respect to the present invention, the only enumerated compounds of the composition are A and B, and further the claim should be interpreted as including equivalents of those compounds.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a graph showing the effect of hFL-11 peptide on HCV viremia in HCV-Trimera mice.
DETAILED DESCRIPTION OF THE INVENTION In a first embodiment, the invention provides an antimicrobial peptide for use in a method of preventing or treating virus infections, wherein the antimicrobial peptide comprises the amino acid sequence GRRRRSVQWCA or ACWQVSRRRRG, or a functional mutant thereof. The antimicrobial peptide preferably comprises or consists of the peptide sequence GRRRRSVQWCA. WO2009028943 describes the antimicrobial effect of antimicrobial peptides comprising the sequence GRRRRSVQWCA and ACWQVSRRRRG. WO2009028943 further shows mutations in said sequence, which show at least the same effect as the original sequence. More in particular, WO2009028943 describes that the following mutations / deletions in a sequence of the invention are equally well or even better than the non-mutated sequences: at least one of the amino acids S, V, Q or W is deleted; one R and at least one of the amino acids S, V, Q or W is deleted; S, V or Q are substituted with a conservative or non-conservative amino acid, provided that (1) the substitute is not a negatively charged amino acid and (ii) S is not substituted with an N; SV, VQ or SQ are substituted with conservative or non-conservative amino acids, provided that none of the substitutes is a negatively charged amino acid; SVQ are substituted with conservative or non-conservative amino acids, provided that none of the substitutes is a negatively charged amino acid; W is replaced by another aromatic amino acid; Q or S is substituted by an aromatic amino acid and W is substituted by a neutral amino acid; C is switched with an amino acid in the SVQW sequence; at least one but no more than three of the R's are substituted by another positively charged amino acid; or the second, third or fourth R is substituted by an A. Therefore, in a preferred embodiment, a functional mutant of the 5 invention is chosen from the group consisting of: a deletion mutant in which at least one of the amino acids S, V, Q or W is deleted; a deletion mutant in which one R and at least one of the amino acids S, V, Q or W is deleted; a substitution mutant in which S, V or Q are substituted with a conservative or non-conservative amino acid, provided that (1) the substitute is not a negatively charged amino acid and (ii) S is not substituted with an N; a double substitution mutant in which SV, VQ or SQ are substituted with conservative or non-conservative amino acids, provided that none of the substitutes is a negatively charged amino acid; a triple substitution mutant in which SVQ are substituted with conservative or non-conservative amino acids, provided that none of the substitutes is a negatively charged amino acid; a substitution mutant in which W is replaced by another aromatic amino acid; a double substitution mutant in which Q or S is substituted by an aromatic amino acid and W is substituted by a neutral amino acid; a substitution mutant in which C is switched with an amino acid in the SVQW sequence; a substitution mutant in which at least one but no more than three of the R's are substituted by another positively charged amino acid; a substitution mutant in which the second, third or fourth R is substituted by an A; and any combination thereof.
Such antimicrobial peptide may be formulated in a pharmaceutical composition. In a second embodiment, therefore, the invention provides a composition comprising an antimicrobial peptide and a pharmaceutically acceptable diluent or excipient, for use in a method of preventing or treating virus infections, wherein the antimicrobial peptide comprises the amino acid sequence GRRRRSVQWCA or ACWQVSRRRRG, or a functional mutant thereof. The antimicrobial peptide preferably comprises or consists of the peptide sequence GRRRRSVQWCA. Such composition is preferably odourless and, preferably colourless, in order to improve patients’ compliance. A colourless and odourless composition can be applied at any time.
An antimicrobial peptide of the invention thus comprises the amino acid sequence RRRRSVQWCA or ACWQVSRRRR, or a functional mutant thereof. In a preferred embodiment, an antimicrobial peptide of the invention consists of the sequence RRRRSVQWCA, GRRRRSVQWCA, ACWQVSRRRRG or ACWQVSRRRR, or a functional mutant thereof. In a preferred embodiment, the antimicrobial peptide consists of GRRRRSVQWCA. In one preferred embodiment, the peptide has been made cyclic. Various methods of cyclization are known to the skilled person, e.g., cys-cys cyclization, backbone-cyclization (= amide bond formation), or thio-ether cyclization. cys-cys cyclization stems from formation of a disulfide (S-S) bond between the thiol side chains of two cysteine residues in a peptide. One disadvantage of cys-cys cyclized peptides is the limited stability of the SS bond, especially under reductive conditions. Amide bond cyclization is also frequently used for cyclic peptides. The bond is chemically more stable than a cys-cys bond. Backbone- amide cyclized peptides are in general prepared via head-to-tail cyclization or side- chain-to-side-chain cyclization. Thio-ether cyclization is performed by reacting the side chain thiol group of a cysteine with the alpha-carbon atom of another amino acid. The reacting amino acids may already be comprised within the sequence of a peptide according to the invention or may be added for this specific purpose. In order for performing cys-cys cyclization in a peptide consisting of the sequence GRRRRSVQWCA, an additional cysteine may for instance be added. CRRRRRSVQWCA may then be cyclized by reacting the thiol groups of both cysteines present.
A peptide according to the invention may further be glycosylated. The skilled person is aware how to chemically glycosylate a peptide as, e.g., described by Crich [15]. An antimicrobial peptide according to the invention may, further to the RRRRSVQWCA or ACWQVSRRRR sequence, or a functional mutant thereof, comprise other amino acids, preferably positively charged amino acids, such as arginine (R) or lysine (K).
An antimicrobial peptide according to the invention may, further to the QWCKQWCK sequence, or a functional mutant thereof, comprise other amino acids, preferably positively charged amino acids, sach as arginine (R).
An antimicrobial peptide according to the invention may, where various modifications or a functional mutant thereof, consists a changed C -Terminal, such as Amidation or N-Terminal, such as Acetylation.
In a preferred embodiment, a composition for use according to the invention is provided, wherein the antimicrobial peptide is present in a concentration of between 1 mg/kg/bodyweight and 16 mg/kg/bodyweight, preferably between 2 mg/kg/bodyweight and 8 mg/kg/bodyweight.
The composition is preferably provided as either a “high concentration therapy” or a “low concentration therapy”, or both. With high and low concentration therapy is meant that the antimicrobial peptide is present in the composition for use according to the invention in a concentration of about 8 mg/kg or of about 640 mg, respectively.
The composition is preferably provided as either a “very high concentration therapy”. With very high concentration therapy is meant that the antimicrobial peptide is present in the composition for use according to the invention in a concentration of about 16 mg/kg/bodyweight, respectively.
In one preferred embodiment, therefore, a composition for use according to the invention is provided, wherein the antimicrobial peptide is present in a concentration between 1 mg/kg/bodyweight and 4 mg/kg/bodyweight, , most preferably of about 2,5 mg/kg/bodyweight. These lower concentrations are in particular useful for maintenance therapy after high dose therapy or for prevention of (new) infections.
The antimicrobial peptide for use according to the invention or composition for use according to the invention is preferably administered at least once daily. Alternatively, the antimicrobial peptide for use according to the invention or composition for use according to the invention is administered at least once every two days, more preferably at least once every two days for at least 2 weeks. More preferably, the peptide or composition is administered at least daily for at least two weeks, more preferably at least 1 month, more preferably for at least 2 months. Preferably, the peptide or composition is administered at least twice a day. More preferably, the peptide or composition is administered at least twice a day for at least 1 month by very serious virus infections.
An antimicrobial peptide as used in the invention has been shown to be broadly active towards a variety of viruses Non-limiting examples of fungi that can be treated with an antimicrobial peptide of the invention are, e.g., In one embodiment, the invention provides a method of treating a patient suffering from virus infection, the method comprising administering a therapeutically effective amount of an antimicrobial peptide comprising the sequence RRRRSVQWCA or ACWQVSRRRR, or a functional mutant thereof to human body affected by Viruses.
Example 1 The composition comprising an antimicrobial peptide of the invention and application thereof The composition used comprises the antimicrobial peptide hLF1-11 (GRRRRSVQWCA) [SEQ ID NO: 3} and is a clear and colorless liquid in a (glass) bottle with a dropper or lotion spray / cream to facilitate application to the skin or hairs of human subjects. The molecular mass of antimicrobial peptide hLF1-11 (GRRRRSVQWCA) [SEQ ID NO: 3} is 1415.6 Da. The composition does not contain preservatives or perfume. The antimicrobial peptide is completely biodegradable. The solution is an aqueous solution comprising 0,01% acetic acid based on the volume of the peptide solution (the composition). The concentration was 3 mg/l antimicrobial peptide based on the total weight of the composition.
The composition 1s suitable for use in the treatment of viruses in a human subject, that are affected by a viral infection.
Furthermore, the composition of the invention comprising the antimicrobial peptide is suitable for use in the treatment or the reduction of symptoms of skin (HPV)..
Moreover, the topical application of the composition comprising the antimicrobial peptide onto the skin of a human subject is suitable for stimulating the natural barrier of the skin (defense system) by preventing new damage by infectious microorganisms such as fungi, bacteria, parasites, mites, algae and viruses. Thus, part of the invention is the composition of the invention comprising the hLF(i-11) peptide [SEQ ID NO: 3] for use in maintaining, controlling, and/or improving the natural barrier function of the skin of a human subject, wherein the natural barrier function of the skin is the prevention or reduction of colonization of said skin by a microbe and/or the prevention or reduction of invasion of the skin and body of said human subject by a microbe such as a bacterium and/or a fungus.
Changes in the microbiota and changes in the immune system can disturb the equilibrium provided by the natural barrier function of the skin of a human subject, and may lead to a range of skin diseases, once the skin does not function properly anymore as the natural barrier against colonization of the skin by a microbe and/or against invasion of the human body by a microbe by entering the body through the skin. The use of the composition comprising the antimicrobial peptide improves the desired and natural well-balanced mix of fungi and bacteria (skin flora), typically existing on a healthy skin. The composition has an immunological effect in the sense that topical application of the composition onto the skin of a human subject maintains or improves the barrier function against microbial infection of the body, which barrier function is provided for by a healthy skin, and application of the composition of the invention provides for an improved or maintained natural protection against colonization, invasion and infection by the fungi and or bacteria that cause dermatophytosis. The first visible improvements are usually observed after two weeks of twice daily topical application of the composition of the invention onto the inflicted skin which is infected by said fungus, fungi, bacterium and/or bacteria and viruses.
Tested viruses: All MIC values ( Cyto Pathologic Effect = CPE) between 40 — 640 microgram/mL - Human cytomegalovirus (only in vitro) - Human Herpes Simplex virus-1 (only in vitro) - Human immunodeficiency virus (only in vitro) - Hepatitis C virus ( in vitro , and also in vivo tested) (in vivo 1 and 4 mg/kg/ mice) - Polio virus (only in vitro) - Rota virus (only in vitro) - Adenovirus (only in vitro) - Enterovirus (only in vitro) - Epstein Barr virus (only in vitro) - Corona virus
PROTOCOLS Basic info: Cell culture is one of the major tools used in cellular and molecular biology. providing excellent model systems for studying the normal physiology and biochemistry of cells (e.g., metabolic studies, aging), the effects of drugs and toxic compounds on the cells, and mutagenesis and carcinogenesis. It is also used in drug screening and development, and large scale manufacturing of biological compounds (e.g., vaccines, therapeutic proteins). The major advantage of using cell culture for any of the these applications is the consistency and reproducibility of results that can be obtained from using a batch of clonal cells.
Viral Propagation Protecol Propagation in Cell Culture A number of ATCC viruses are propagated in cell culture. Typically, propagation hosts are grown in tissue culture vessels (such as T flasks) using media and reagents specified for the host cell line. Most cell lines are seeded the day prior to setting up an infection and should not be seeded more than two days in advance, nor passaged more than 9 times prior to infection. In addition to setting up cells for infection, negative control cells should also be set up to monitor cellular health.
1. Identify the recommended propagation host as indicated on the product sheet. Plan to use the propagation host.
2. Prepare the cell growth medium for growing the host cell line.
3. Prepare the virus growth medium as recommended on the product sheet.
4. One to two days prior to inoculation seed the host cells. Be sure to include a vessel that will not be inoculated with virus to serve as a negative control.
5. Allow cells to reach the appropriate confluency.
6. Prior to thawing the frozen virus stock check the virus titer listed on the certificate of analysis. Quickly thaw the virus in a 37°C water bath.
7. Dilute the virus stock in the appropriate volume of viral growth medium.
8. Remove the cell growth medium from the cell culture flasks.
9. Inoculate the diluted virus to provide an optimal MOI as indicated on the product sheet.
10. Incubate tissue cultures under the appropriate temperature and atmospheric conditions for the recommended incubation period. 11, After the recommended incubation time period, check the flask for cytopathic effects (CPE) when applicable. Tissue Culture Infectious Dose (TCID) Viral titer can be determined in vitro by calculating the infectious dose. For tissue culture-adapted strains, this calculation is ascertained through an endpoint dilution assay in cell culture. The most reproducible endpoint of the dilution assay is the dilution of the virus that will produce a pathological change in 50% of the cell cultures inoculated. This number is expressed as 50% the infectious dose, or
TCIDso, which is analogous to the calculation for lethal dose 50. The accuracy of this method is related to the number of replicates at each dilution’.
1. Prepare a cell culture plate with the recommended cell line for viral propagation (preferably the same cells that the virus being tested was grown in).
2. Incubate the plate under the appropriate conditions for cell growth until cells reach an optimum density for infection.
3. Prepare viral dilutions in base medium.
4. Remove cell growth medium from plate, the monolayer may be washed with remove any inhibitory agents.
5. Inoculate at least 3 wells with each dilution. Be sure to inoculate wells with base medium to serve as negative controls. Use a fresh, sterile pipette for each dilution.
6. Allow the plate to incubate for 1 to 2 hours under conditions suitable for virus adsorption.
7. Add viral growth medium and incubate the plate under conditions suitable for the virus and observe all wells daily. Record results for each well daily.
8. The endpoint is determined when the CPE or immunofluorescence assay (IFA) read-out appear the same per dilution for 3 separate readings.
9. The titer is calculated using the method of Reed and Muench. A titer expressed as 10(3.0)TCIDs/0.2 mL in 3 days in XXXX cell line may be translated as: 0.2 mL of virus diluted at 1:1000 will infect 50% of the cells in 3 days when using XXXX cell line. XXXX cell line can be HeLa cells, MRC-5 or Vero cell lines. Example 2 Effect of hLF1-11 peptide on HCV viremia in HCV-Trimera mice Evaluation of the effects of hLF1-11 peptide on established viremia in the HCV —Trimera mouse Model.
This study consists of tree experimental groups: 1 Control, saline treated animals (i.p.: Q.D.; n=16). 2 Treatment with I mg/kg/day of hLF1-11 peptide (1.p.; Q.D.; n=15). 3 Treatment with 4 mg/kg/day of hLF1-11 peptide (i.p.; Q.D.; n=16).
Treatment with saline solution of hLFI-11 peptide or with saline (control) was given from day 7 to day 20 post transplantation (total of 14 days). Bleeds were taken at day 21 (one day post treatment completion). Sera samples were further evaluated. Results: Day 21 post transplantation Group Mean viral load £ SE % of HCV — (HCV-RNA copies/ml serum) positive mice
1. Control, saline treated Animals (i.p.; Q.D.; n=16). 6.55x104 + 1.0x104 88 (14/16)
2. Treatment with 1 mg/kg/day of hLFi-11 (i.p.; Q.D.; n=19). 7,83x103 + 2.0x103 53 (8/15)
3. Treatment with 4 mg/kg/day of hLF1-11 (i.p.; Q.D.; n=15). 3.28x103 £5.0x102 19 (3/16) The results are also summarized in the attached figure. The percentages of HCV-positive mice are given in parentheses and the viral loads are given as Mean Viral Load + SE.
Differences in percentages of HCV-positive animals between control and treated groups of mice are compared using Fisher's exact test analysis. Differences in viral loads between control and treated groups of mice (group pairs) are compared by the non-parametric Mann-Whitney U test.
The effect of hFL-11 peptide on HCV viremia in HCV-Trimera mice is shown in the graph of Figure 1.
Conclusions:
1. In this experiment and under specific conditions hLF1-11 peptide shows anti-HCV activity in the HCV- Trimera mouse model.
2. In this experiment and under specific conditions hLF1-11 peptide did not cause observable toxic effects in the mice.
3. Results should be confirmed in repeated experiments in order to decide how to proceed (dose range). Blood samples should be taken one day post-treatment completion and 3-5 days later (post effect).
4. It is suggested to use, as negative control, a non-active peptide (scrambled peptide (MW= 1,5 KDa).
3195 Seqlist amended
SEQUENCE LISTING <110> CBMR Scientific Nanoscience B.V. <120> ANTIMICROBIAL PEPTIDE FOR TREATMENT AND CONTROLLING VIRUS INFECTIONS <130> P.CBMR/NL-3195 <140> NL2025294 <141> 2020-04-07 <160> 7 <170> PatentIn version 3.5 <210> 1 <211> 10 <212> PRT <213> Homo sapiens <400> 1 Arg Arg Arg Arg Ser Val Gln Trp Cys Ala 1 5 10 <210> 2 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Reverse hLF2-11 <400> 2 Ala Cys Trp Gln Val Ser Arg Arg Arg Arg 1 5 10 <210> 3 <211> 11 <212> PRT <213> Homo sapiens <400> 3 Gly Arg Arg Arg Arg Ser Val Gln Trp Cys Ala 1 5 10 <210> 4 <211> 11 <212> PRT <213> Artificial Sequence <220> Pagina 1
3195 Seqlist amended <223> Reverse hLF1-11 <400> 4 Ala Cys Trp Gln Val Ser Arg Arg Arg Arg Gly 1 5 10 <210> 5 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> cysteine - hLF1-11 <400> 5 Cys Gly Arg Arg Arg Arg Ser Val Gln Trp Cys Ala 1 5 10 <210> 6 <211> 4 <212> PRT <213> Artificial Sequence <400> 6 Ser Val Gln Trp 1 <210> 7 <211> 12 <212> PRT <213> Artificial Sequence <400> 7 Cys Arg Arg Arg Arg Arg Ser Val Gln Trp Cys Ala 1 5 10
Pagina 2
Claims (3)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025294A NL2025294B1 (en) | 2020-04-07 | 2020-04-07 | Antimicrobial peptide for treatment and controlling virus infections |
| NL2027924A NL2027924B1 (en) | 2020-04-07 | 2021-04-06 | Antimicrobial peptide for prevention and treatment of virusinfections |
| PCT/NL2021/050224 WO2021206548A1 (en) | 2020-04-07 | 2021-04-06 | Antimicrobial peptide for treatment and controlling virus infections |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2025294A NL2025294B1 (en) | 2020-04-07 | 2020-04-07 | Antimicrobial peptide for treatment and controlling virus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2025294B1 true NL2025294B1 (en) | 2021-10-25 |
Family
ID=73699370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2025294A NL2025294B1 (en) | 2020-04-07 | 2020-04-07 | Antimicrobial peptide for treatment and controlling virus infections |
| NL2027924A NL2027924B1 (en) | 2020-04-07 | 2021-04-06 | Antimicrobial peptide for prevention and treatment of virusinfections |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2027924A NL2027924B1 (en) | 2020-04-07 | 2021-04-06 | Antimicrobial peptide for prevention and treatment of virusinfections |
Country Status (2)
| Country | Link |
|---|---|
| NL (2) | NL2025294B1 (en) |
| WO (1) | WO2021206548A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0769915A (en) * | 1993-09-02 | 1995-03-14 | Snow Brand Milk Prod Co Ltd | Viral infection/proliferation inhibitor |
| EP2030980A1 (en) * | 2007-08-28 | 2009-03-04 | AM-Pharma B.V. | Mutants of lactoferrin |
| US20090142298A1 (en) * | 2007-09-05 | 2009-06-04 | Shatunovskiy Nikolay E | Apolactoferrin Compositions and Methods for Their Use in the Treatment of Viral Hepatitis C |
-
2020
- 2020-04-07 NL NL2025294A patent/NL2025294B1/en not_active IP Right Cessation
-
2021
- 2021-04-06 NL NL2027924A patent/NL2027924B1/en not_active IP Right Cessation
- 2021-04-06 WO PCT/NL2021/050224 patent/WO2021206548A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0769915A (en) * | 1993-09-02 | 1995-03-14 | Snow Brand Milk Prod Co Ltd | Viral infection/proliferation inhibitor |
| EP2030980A1 (en) * | 2007-08-28 | 2009-03-04 | AM-Pharma B.V. | Mutants of lactoferrin |
| WO2009028943A1 (en) | 2007-08-28 | 2009-03-05 | Am-Pharma B.V. | Mutants of lactoferrin |
| US20090142298A1 (en) * | 2007-09-05 | 2009-06-04 | Shatunovskiy Nikolay E | Apolactoferrin Compositions and Methods for Their Use in the Treatment of Viral Hepatitis C |
Non-Patent Citations (3)
| Title |
|---|
| ALLAIRE ANDRÉA ET AL: "Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus", JOURNAL OF VISUALIZED EXPERIMENTS, no. 104, 1 January 2015 (2015-01-01), XP055781354, DOI: 10.3791/53053 * |
| JENSSEN H ET AL: "Antimicrobial properties of lactoferrin", BIOCHIMIE, MASSON, PARIS, FR, vol. 91, no. 1, 1 January 2009 (2009-01-01), pages 19 - 29, XP025869223, ISSN: 0300-9084, [retrieved on 20080605], DOI: 10.1016/J.BIOCHI.2008.05.015 * |
| JENSSEN H: "Anti herpes simplex virus activity of lactoferrin/lactoferricin - an example of antiviral activity of antimicrobial protein/peptide", CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHÄUSER-VERLAG, BA, vol. 62, no. 24, 1 December 2005 (2005-12-01), pages 3002 - 3013, XP019200911, ISSN: 1420-9071, DOI: 10.1007/S00018-005-5228-7 * |
Also Published As
| Publication number | Publication date |
|---|---|
| NL2027924A (en) | 2021-10-25 |
| WO2021206548A1 (en) | 2021-10-14 |
| NL2027924B1 (en) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6835713B2 (en) | Virus derived antimicrobial peptides | |
| US20020188102A1 (en) | Virus derived antimicrobial peptides | |
| CN112552379B (en) | Application of synthetic peptide in preparation of medicine for preventing and treating novel coronavirus infection | |
| AU2015336933B2 (en) | A method of treatment | |
| US20060287232A1 (en) | Antimicrobial peptides | |
| BR0214188A (en) | Monoclonal antibodies to hepatitis viruses and / or fragments thereof with binding activity and use thereof | |
| CN110740745A (en) | Pharmaceutical compositions containing glutathione disulfide and glutathione disulfide S-oxide | |
| KR20180037185A (en) | A broad spectrum of anti-infective peptides | |
| US10413586B2 (en) | Antiviral agent comprising recombinant mistletoe lectins | |
| US20030036627A1 (en) | Virus derived antimicrobial peptides | |
| KR102393872B1 (en) | Antiviral peptide from M2 protein and the use thereof | |
| NL2025294B1 (en) | Antimicrobial peptide for treatment and controlling virus infections | |
| Avram et al. | Evaluation of the therapeutic properties of mastoparan-and sifuvirtide-derivative antimicrobial peptides using chemical structure-function relationship-in vivo and in silico approaches | |
| CN116769048A (en) | Polymeric molecules, including their single and multimeric structures | |
| Docherty et al. | Inactivation of herpes simplex virus types 1 and 2 by synthetic histidine peptides | |
| CN108409833B (en) | A novel candida killing polypeptide FCP1 and preparation method thereof | |
| JP3770624B2 (en) | Virus infection / proliferation inhibitor | |
| CN114762694A (en) | Use of oligosaccharyl transferase inhibitors for the prevention and/or treatment of novel coronavirus infections | |
| SK29795A3 (en) | Inhibition of retrovirus infection | |
| EP1368050B1 (en) | Virus derived antimicrobial peptides | |
| CN112641929B (en) | Antiviral application of host defense peptides in Periplaneta americana | |
| US20090028820A1 (en) | Antiviral Agent | |
| US20240018207A1 (en) | Interferon tau fc-fusion proteins and methods for treating coronavirus infections | |
| CN115957302A (en) | A kind of compound preparation LL-37-cGAMP and its preparation method and application | |
| JP4188897B2 (en) | Virus infection / proliferation inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Lapsed because of non-payment of the annual fee |
Effective date: 20230501 |